Alnylam Pharmaceuticals, Inc., 10% Owner at Regulus Therapeutics Inc. ("RGLS"), sold 5,000 shares at $6.96 ($35K) on 2014-08-28, disclosed to the SEC on 2014-08-29.
Scheduled sale ($35k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.21 | 1,500 | $11K | 30.9% |
| 2 | $6.96 | 2,000 | $14K | 39.8% |
| 3 | $6.84 | 1,500 | $10K | 29.3% |
| Total | $7.00 avg | 5,000 | $35K | 100% |
| Filing → |
| RGLS | SELL | 2014-10-24 | $1.6M | — | Filing → |
| RGLS | SELL | 2014-10-17 | $81K | — | Filing → |
| RGLS | SELL | 2014-10-10 | $66K | — | Filing → |